Starling Oncology, Inc. (STLN) Operating cash flow 2020–2025
Starling Oncology, Inc. (STLN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$24.6MFY2025 · since FY2020: $508,000 → -$24.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$24.6M | +7.4% |
| FY2024 | -$26.5M | +26.9% |
| FY2023 | -$36.3M | +41.2% |
| FY2022 | -$61.8M | -89.0% |
| FY2021 | -$32.7M | -6533.1% |
| FY2020 | $508,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STLN financial trends
STLN RevenueSTLN Net incomeSTLN Net marginSTLN Gross profitSTLN Gross marginSTLN Operating incomeSTLN Operating marginSTLN Free cash flowSTLN Capital expendituresSTLN Return on equitySTLN Stock buybacksSTLN Dividends paidSTLN Total assetsSTLN Total liabilitiesSTLN Shareholders’ equitySTLN overview →